G. Masucci

发表

Cancer classification using the Immunoscore: a worldwide task force

F. Marincola, P. Gibbs, M. Mihm, 2012, Journal of Translational Medicine.

Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

F. Marincola, P. Gibbs, P. Delrio, 2013, The Journal of pathology.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

F. Marincola, D. Sargent, P. Delrio, 2018, The Lancet.

Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome.

E. Andersson, I. Zlobec, V. Koelzer, 2015, Translational research : the journal of laboratory and clinical medicine.

A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients

R. Kiessling, B. Glimelius, K. Malmberg, 2007, Cancer Immunology, Immunotherapy.

World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016

F. Marincola, P. Ascierto, J. Galon, 2017, Journal of Translational Medicine.

Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology

E. Petricoin, L. Liotta, F. Marincola, 2009, Journal of Translational Medicine.

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges

Daniel K. Wells, V. Thorsson, J. Kirkwood, 2020, Journal for ImmunoTherapy of Cancer.

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges

Daniel K. Wells, V. Thorsson, J. Kirkwood, 2020, Journal for ImmunoTherapy of Cancer.

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy

F. Marincola, J. Taube, P. Ascierto, 2017, Journal of Translational Medicine.

HLA Class I and II Expression in Oropharyngeal Squamous Cell Carcinoma in Relation to Tumor HPV Status and Clinical Outcome

T. Nyberg, E. Andersson, E. Munck‐Wikland, 2013, PloS one.

Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma

G. Wagenius, J. Hansson, G. Masucci, 2006, Melanoma research.

A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer.

R. Kiessling, B. Glimelius, K. Malmberg, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Block of NFT Cells by Oxidative Stress Associated with ) + Inhibition of Activated / Memory ( CD 45 RO

S. Pettersson, K. Malmberg, G. Masucci, 2001 .

Interleukin 10 pretreatment protects target cells from tumor- and allo- specific cytotoxic T cells and downregulates HLA class I expression

M. Matsuda, R. Kiessling, M. Masucci, 1994, The Journal of experimental medicine.

Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF).

J. Fagerberg, A. Osterborg, C. Lindemalm, 1991, Acta oncologica.

Effect of monoclonal antibody 17‐1A and gm‐CSF in patients with advanced colorectal carcinoma—long‐lasting, complete remissions can be induced

J. Fagerberg, C. Lindemalm, G. Masucci, 1993, International journal of cancer.

The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1a in combination with GM-CSF in the treatment of COLORECTAL CARCINOMA (CRC)

G. Masucci, H. Mellstedt, P. Ragnhammar, 1993, Medical Oncology and Tumor Pharmacotherapy.

Sex Differences in Overall Survival and the Effect of Radiotherapy in Merkel Cell Carcinoma—A Retrospective Analysis of A Swedish Cohort

W. Lui, G. Masucci, L. Villabona, 2021, Cancers.

PD-L1 expression as a potential predictive biomarker.

P. Ascierto, I. Melero, P. Lorigan, 2015, The Lancet. Oncology.

Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial

U. Isacsson, R. Kiessling, R. Lewensohn, 2022, Acta oncologica.

SRF-CLICAL: an approach for patient risk stratification using random forest models

Felipe A. Simão, G. Madonna, P. Ascierto, 2021, bioRxiv.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016, Journal for ImmunoTherapy of Cancer.

Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer.

T. Dalianis, G. Masucci, L. Villabona, 2006, Gynecologic oncology.

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

G. Madonna, D. Mallardo, P. Ascierto, 2021, Cancers.

Will modern cancer vaccines reach clinical practice?

G. Masucci, 1999, Medical oncology.

Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real‐world setting

M. Bottai, H. Eriksson, K. Smedby, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours

R. Kiessling, R. Lewensohn, P. Wersäll, 2012, Journal of Translational Medicine.

Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer.

B. Seliger, E. Andersson, R. Kiessling, 2007, Tissue antigens.

E. Lennette, G. Klein, G. Masucci, 1993, European journal of cancer.

Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases

R. Lewensohn, P. Wersäll, G. Masucci, 2022, Clinical and translational radiation oncology.

Effects of human plasma proteins on maturation of monocyte-derived dendritic cells.

P. Pisa, G. Masucci, A. Lundqvist, 2005, Immunology letters.

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.

D. Sargent, P. Ascierto, B. Fox, 2016 .

PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates

R. Kiessling, J. Hansson, T. Nakajima, 2020, Oncoimmunology.

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1

P. Coulie, Y. Humblet, B. Dréno, 1999, International journal of cancer.

Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

R. Kiessling, R. Tell, J. Hansson, 2020, Oncoimmunology.

HLA-dependent tumour development: a role for tumour associate macrophages?

B. Seliger, E. Andersson, R. Kiessling, 2013, Journal of Translational Medicine.

Restricted T cell receptor V-β and J-β usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas

E. Halapi, R. Kiessling, H. Mellstedt, 2005, Cancer Immunology, Immunotherapy.

Oligoclonal T Cells Expressing the TCR V-ß 6 Gene Product Following IL-2 Culture of Ovarian Carcinoma Derived Lymphocytes

E. Halapi, R. Kiessling, H. Mellstedt, 1992 .

Diverse effect of cytokine treatment of tumor cells on specific versus non-specific cytotoxicity

E. Halapi, R. Kiessling, H. Mellstedt, 1992, Medical oncology and tumor pharmacotherapy.

Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy

R. Lewensohn, G. Masucci, M. Ålenius, 2005, Medical oncology.

New clinical applications of granulocyte-macrophage colony-stimulating factor.

G. Masucci, 1996, Medical oncology.

A novel approach for HLA-A typing in formalin-fixed paraffin-embedded-derived DNA

B. Seliger, E. Andersson, T. Dalianis, 2014, Modern Pathology.

Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.

E. Halapi, R. Kiessling, H. Mellstedt, 1993, Cancer immunology, immunotherapy : CII.

Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity

H. Mellstedt, P. Wersäll, G. Masucci, 2004, Cancer Immunology, Immunotherapy.

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma

R. Kiessling, Yuan Yang, J. Hansson, 2017, Oncotarget.

Generation of human LAK cells in tissue culture bags using recombinant IL-2 and serum free medium. Effects of pretreatment with phenylalanine-methylester.

H. Mellstedt, I. Cotgreave, H. Wigzell, 1990, Acta oncologica.

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer

R. Kiessling, A. Miller, S. Nilsson, 2004, British Journal of Cancer.

Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis.

H. Blomgren, I. Ernberg, O. Weiland, 1984, Clinical immunology and immunopathology.

Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study

F. Marincola, P. Delrio, J. Lee, 2022, Cancers.

Cells and cytokines in immunotherapy and gene therapy of cancer.

R. Rees, G. Pawelec, R. Kiessling, 1999, Critical reviews in oncogenesis.

Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006

N. Ibrahim, A. Ribas, C. Blank, 2017 .

Immunological characterization of Hodgkin's and non-Hodgkin's lymphoma patients with high antibody titers against Epstein-Barr virus-associated antigens.

I. Ernberg, M. Masucci, M. Björkholm, 1984, Cancer research.

Production of leukocyte migration inhibitory factor (LIF) in human lymphocyte subsets exposed to polyclonal activators.

G. Klein, M. Masucci, K. Bendtzen, 1984, Cellular immunology.

EGNA-specific LIF production of human lymphocyte subsets.

G. Klein, E. Klein, W. Henle, 1984, Cellular immunology.

The therapeutic use of monoclonal antibodies in colorectal carcinoma.

J. Fagerberg, J. Shetye, A. Osterborg, 1991, Seminars in oncology.

Dendritic cells highly quoted on immunotherapy stock market

G. Masucci, 2002, Medical oncology.

Studies on cytotoxicity generated in human mixed lymphocyte cultures. II. Anti-K562 effectors are distinct from allospecific CTL and can be generated from NK-depleted T cells.

E. Klein, G. Masucci, S. Golub, 1979, Journal of immunology.

Cellular immune defects to Epstein-Barr virus-determined antigens in young males.

I. Ernberg, G. Klein, M. Masucci, 1981, Cancer research.

Epstein-Barr virus (EBV)-specific cell-mediated and humoral immune responses in ataxia-telangectasia patients

I. Ernberg, G. Klein, F. Ersoy, 1984, Journal of Clinical Immunology.

Analysis of Epstein-Barr virus-specific and non-specific immune functions in a patient during the development of a non-Hodgkin's lymphoma.

I. Ernberg, G. Klein, M. Masucci, 1987, European journal of cancer & clinical oncology.

Natural killer activity of human blood lymphocytes.

M. Masucci, E. Klein, G. Masucci, 1982, Molecular immunology.

HUMAN BLOOD LYMPHOCYTE SUBSETS CHARACTERIZED BY MONOCLONAL REAGENTS

M. Masucci, E. Klein, G. Masucci, 1982 .

Interleukin-4 augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity

H. Mellstedt, P. Wersäll, G. Masucci, 2005, Cancer Immunology, Immunotherapy.

Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines

R. Kiessling, F. Salazar-Onfray, G. Masucci, 2012, Cancer Immunology, Immunotherapy.

Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor

G. Masucci, H. Mellstedt, P. Ragnhammar, 2005, Cancer Immunology, Immunotherapy.

Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A)

H. Mellstedt, P. Wersäll, G. Masucci, 2005, Cancer Immunology, Immunotherapy.

Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAb 17-1A: a combination of potential usefulness in tumor therapy.

J. Nielsen, H. Mellstedt, H. Wigzell, 1989, Hybridoma.

Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and Br55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948).

C. Lindemalm, G. Masucci, H. Mellstedt, 1988, Hybridoma.

Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma

J. Fagerberg, J. Wersäll, C. Lindemalm, 1993, Medical oncology and tumor pharmacotherapy.

Target selectivity of interferon-induced human killer lymphocytes related to their Fc receptor expression.

M. Masucci, E. Klein, G. Masucci, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Comparison of highly NK active human lymphocyte subsets separated by various procedures involving E, EA rosetting, density gradients and adherence to immune complexes.

M. Masucci, E. Klein, G. Masucci, 1983, Journal of immunological methods.

Human blood lymphocyte subsets separated on the basis of nylon adherence, SRBC and EA rosetting: natural cytotoxicity and characterization with monoclonal reagents.

M. Masucci, E. Klein, G. Masucci, 1982, Cellular immunology.

Relationship between clinical stage, histopathology and antibody titers against the second epstein‐barr virus nuclear antigen (EBNA‐2) in non‐Hodgkin's lymphoma patients

I. Ernberg, G. Klein, M. Masucci, 1989, International journal of cancer.

GM-CSF at Relatively high topic concentrations can significantly enhance the healing of surgically induced chronic wounds after radiotherapy

S. Friesland, J. Fernberg, G. Masucci, 2001, Medical oncology.

T-Cell Response to B-Cells and Epstein-Barr Virus Antigens in Infectious Mononucleosis1

I. Ernberg, G. Masucci, E. Svedmyr, 2006 .

T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis.

I. Ernberg, M. Masucci, G. Masucci, 1981, Cancer research.

Development of a technology platform for large-scale clinical grade production of DC.

H. Mellstedt, P. Pisa, G. Masucci, 2004, Cytotherapy.

In vitro generation of K562 killers in human T-lymphocyte subsets.

E. Klein, G. Masucci, A. Poros, 1980, Cellular immunology.

Somatic hybrids between a high NK-sensitive lymphoid (YACIR) and several low sensitive sarcoma or L-cell-derived mouse lines exhibit low sensitivity

E. Klein, L. Ährlund‐Richter, G. Masucci, 1980, Somatic cell genetics.

Simplified long term large scale production of highly active human lak cells for therapy

H. Mellstedt, P. Wersäll, G. Masucci, 1990, Medical oncology and tumor pharmacotherapy.

Mab 17-1A Used for Therapy of Patients with Metastatic Colorectal Carcinomas

B. Ahlman, J. Shetye, U. Harmenberg, 1989 .

Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis).

R. Kiessling, J. Hansson, T. Nakazawa, 1997, Journal of hematotherapy.

Cell-mediated Immune Reactions in Three Patients with Malignant Lymphoproliferative Diseases in Remission and Abnormally High Epstein-Barr Virus Antibody Titers 1

I. Ernberg, G. Klein, M. Masucci, 2006 .

Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17–1A develop a cellular response (DTH) to the “internal image of the antigen” (ab2)

J. Fagerberg, P. Biberfeld, M. Steinitz, 1991, International journal of cancer.

Activation of human blood lymphocyte subsets for cytotoxic potential.

M. Masucci, E. Klein, G. Masucci, 1982, Cellular immunology.

Defining the critical hurdles in cancer immunotherapy

Zhigang Tian, Sylvia Janetzki, Cedrik M Britten, 2011, Journal of Translational Medicine.

Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.

A. Sette, E. Appella, R. Kiessling, 1997, Cancer research.

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma

D. Mougiakakos, R. Kiessling, J. Hansson, 2009, Cancer Immunology, Immunotherapy.

Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis

B. Seliger, E. Andersson, R. Kiessling, 2015, Oncoimmunology.

Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer

B. Seliger, E. Andersson, R. Kiessling, 2012, Cancer Immunology, Immunotherapy.

Clinical status of monoclonal antibodies in the treatment of colorectal carcinoma.

G. Masucci, H. Mellstedt, J. Frodin, 1989, Oncology.

Monoclonal antibodies (MAb 17-1A) for the treatment of patients with metastatic colorectal carcinomas.

J. Shetye, P. Biberfeld, B. Christensson, 1989, Acta chirurgica Scandinavica. Supplementum.

Biologic therapeutics as the fourth modality in cancer treatment.

H. Mellstedt, G. Masucci, 1990, Leukemia.

Hydrogen peroxide secreted by tumor‐derived macrophages down‐modulates signal‐transducing zeta molecules and inhibits tumor‐specific T cell‐and natural killer cell‐mediated cytotoxicity

P. Anderson, R. Kiessling, J. Hansson, 1996, European journal of immunology.

Studies on cytotoxicity generated in human mixed lymphocyte cultures. II. Anti-K562 effectors are distinct from allospecific CTL and can be generated from NK-depleted T cells.

E. Klein, G. Masucci, S. Golub, 1978, Journal of immunology.

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014

Martin F. Mihm, B. Schilling, F. Marincola, 2013, Journal of Translational Medicine.

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

F. Marincola, J. Taube, G. Botti, 2013, Journal of Translational Medicine.

Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer

C. Klein, T. Sjöblom, B. Glimelius, 2020, Cancers.

Chemotherapy and immunotherapy of colorectal cancer

J. Fagerberg, H. Mellstedt, A. Österborg, 1991, Medical oncology and tumor pharmacotherapy.

The clinical use of monoclonal antibodies, MAb 17-1A, in the treatment of patients with metastatic colorectal carcinoma

J. Shetye, U. Harmenberg, P. Biberfeld, 1989, Medical oncology and tumor pharmacotherapy.

Biologic response modifiers in the treatment of gastrointestinal malignancies.

M. Steinitz, C. Lindemalm, P. Wersäll, 1989, Scandinavian journal of gastroenterology.

Gamma‐interferon (IFN‐γ) produced during effector and target interactions renders target cells less susceptible to NK‐cell‐mediated lysis

G. Klein, R. Kiessling, G. Masucci, 1983, International journal of cancer.

A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins.

P. Lollini, G. Forni, M. Iezzi, 2010, Cancer research.

Interferon suppresses antigen- and mitogen-induced leukocyte migration inhibition

M. Masucci, E. Klein, G. Klein, 1980, Nature.

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)

F. Marincola, G. Botti, P. Ascierto, 2018, Journal of Translational Medicine.

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

K. Dobbin, L. Butterfield, S. Selvan, 2016, Journal of Immunotherapy for Cancer.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Genotyping of human leukocyte antigen (HLA) ancestral haplotypes as prognostic marker in cancer using PCR analysis.

E. Andersson, G. Masucci, L. Villabona, 2014, Methods in molecular biology.

Survival of the fittest or best adapted: HLA-dependent tumor development

B. Seliger, E. Andersson, G. Forni, 2010 .

A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma

E. Andersson, R. Kiessling, R. Tell, 2014, Cancer Immunology, Immunotherapy.

NATURAL AND ACTIVATED LYMPHOCYTE KILLERS WHICH AFFECT TUMOR CELLS1

M. Masucci, E. Klein, G. Masucci, 1980 .

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations

K. Dobbin, L. Butterfield, S. Selvan, 2016, Journal of Immunotherapy for Cancer.

Inhibition of Activated/Memory (CD45RO+) T Cells by Oxidative Stress Associated with Block of NF-κB Activation1

R. Kiessling, S. Pettersson, K. Malmberg, 2001, The Journal of Immunology.

Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer

F. Marincola, P. Delrio, J. Lee, 2023, Cancers.

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.

F. Marincola, P. Delrio, G. Botti, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015

F. M. Marincola, F. Marincola, G. Botti, 2016, Journal of Translational Medicine.

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

J. Hipp, C. Horak, G. Botti, 2016, Drugs.

The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma

B. Seliger, E. Andersson, R. Kiessling, 2009, Cancer Immunology, Immunotherapy.

Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

D. Mougiakakos, R. Kiessling, J. Hansson, 2010, Cancer research.

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production

R. Kiessling, J. Hansson, G. Masucci, 2014, Journal of Translational Medicine.

Cell-mediated immune reactions in three patients with malignant lymphoproliferative diseases in remission and abnormally high Epstein-Barr virus antibody titers.

I. Ernberg, G. Klein, M. Masucci, 1981, Cancer research.

Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells.

M. Masucci, E. Klein, G. Masucci, 1983, Cellular immunology.

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

S. H. van der Burg, F. Marincola, A. Palucka, 2011, Clinical Cancer Research.

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.

B. Seliger, R. Kiessling, D. Atkins, 2006, Cancer research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

W. Miller, N. Ibrahim, C. Robert, 2017, European journal of cancer.

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)

F. Marincola, G. Botti, P. Ascierto, 2019, Journal of Translational Medicine.

T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy

R. Kiessling, R. Lewensohn, G. Masucci, 2015 .

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma

J. Lapins, H. Tawbi, M. Tetzlaff, 2020, Acta dermato-venereologica.

Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists

M. Nishimura, R. Kiessling, A. Karlsson-Parra, 2017, Cancer Immunology, Immunotherapy.

A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

Yingdong Zhao, Holden Maecker, Sylvia Janetzki, 2008, Journal of Translational Medicine.

Leukocyte migration inhibitory factor production by activated lymphocytes representing immunological memory or virus-receptor interaction: response of T cell subsets to Epstein-Barr virus nuclear antigen, response of B cells to UV inactivated Epstein-Barr virus.

M. Masucci, E. Klein, P. Åman, 1985, Immunology letters.

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013

B. Schilling, F. Marincola, R. Sullivan, 2014, Journal of Translational Medicine.

Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy

R. Kiessling, J. Hansson, G. Masucci, 2014, Cancer Immunology, Immunotherapy.

Miniatures Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase 1 Production

R. Kiessling, J. Hansson, G. Masucci, 2013 .

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.

R. Kiessling, J. Hansson, I. Schultz, 2013, Cancer research.

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.

P. Ascierto, R. Kefford, J. Hansson, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. I. Isolation, characterization, cell surface markers, and B-cell markers.

S. Povey, J. Zeuthen, P. Ralph, 1982, Journal of the National Cancer Institute.

Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1).

S. Povey, J. Zeuthen, G. Klein, 1980, Journal of the National Cancer Institute.

Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates

P. Pisa, G. Masucci, A. Lundqvist, 2004, Medical oncology.

Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?

P. Unger, A. Lefvert, H. Mellstedt, 1991, Hybridoma.

Protein profiling of fine‐needle aspirates reveals subtype‐associated immune signatures and involvement of chemokines in breast cancer

U. Landegren, A. Alexeyenko, R. Lewensohn, 2019, Molecular oncology.

EFFECT OF IFN AND PHA ON THE CYTOTOXIC ACTIVITY OF BLOOD LYMPHOCYTE SUBSETS

M. Masucci, E. Klein, G. Masucci, 1982 .

An Italian Case of Nasopharyngeal Carcinoma Correlated with Epstein-Barr Virus Specific Antigens

G. Masucci, E. Cassai, Rosario Scolozzi, 1977, Tumori.

Combinations of IL-2, GM-CSF, IL-4, IFN-α and TNF-α increase the antibody dependent cellular cytotoxicity (ADCC) of blood mononuclear cells in presence of either mouse or chimeric MAb 17-1A : a preclinical evaluation

H. Mellstedt, G. Masucci, 1991 .

World-Wide Immunoscore Task Force: meeting report from the “Melanoma Bridge”, Napoli, November 30th–December 3rd, 2016

F. Marincola, P. Ascierto, J. Galon, 2017, Journal of Translational Medicine.

HLA-A*02 in relation to outcome in human papillomavirus positive tonsillar and base of tongue cancer.

A. Näsman, T. Ramqvist, T. Dalianis, 2014, Anticancer research.

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)

F. Marincola, G. Botti, P. Ascierto, 2019, Journal of Translational Medicine.

Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis

D. Mallardo, G. Botti, P. Ascierto, 2021, Journal of translational medicine.

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours

R. Kiessling, R. Lewensohn, P. Wersäll, 2012, Journal of Translational Medicine.

Future perspectives in melanoma research

F. Marincola, J. Taube, G. Botti, 2016, Journal of Translational Medicine.

Planning a Bayesian early‐phase phase I/II study for human vaccines in HER2 carcinomas

Dario Gregori, Ileana Baldi, Sarah Zohar, 2011, Pharmaceutical statistics.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Future perspectives in melanoma research

F. Marincola, J. Taube, G. Botti, 2016, Journal of Translational Medicine.

Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014

Martin F. Mihm, B. Schilling, F. Marincola, 2013, Journal of Translational Medicine.

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

F. Marincola, J. Taube, G. Botti, 2013, Journal of Translational Medicine.

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production

R. Kiessling, J. Hansson, G. Masucci, 2013, Journal of Translational Medicine.

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.

R. Kiessling, J. Hansson, I. Schultz, 2013, Cancer research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Persistence of Epstein‐barr viral nuclear antigen (EBNA) in cells entering the eb viral cycle

I. Ernberg, G. Klein, G. Masucci, 1976, International journal of cancer.

Interferon-gamma enhances monoclonal antibody 17-1A-dependent neutrophil cytotoxicity toward colorectal carcinoma cell line SW11-16.

R. Gambari, R. Gavioli, G. Masucci, 1994, Clinical immunology and immunopathology.

GM-CSF augments the IL-4-induced cytotoxic activity of human mononuclear cells in the presence of the mouse monoclonal antibody 17-1A

H. Mellstedt, G. Masucci, E. Reali, 1993 .